ATE425745T1 - Medikament auf der basis von ein antihyperglykamikum enthaltenden mikrokapseln mit gesteuerter freisetzung - Google Patents

Medikament auf der basis von ein antihyperglykamikum enthaltenden mikrokapseln mit gesteuerter freisetzung

Info

Publication number
ATE425745T1
ATE425745T1 AT01996365T AT01996365T ATE425745T1 AT E425745 T1 ATE425745 T1 AT E425745T1 AT 01996365 T AT01996365 T AT 01996365T AT 01996365 T AT01996365 T AT 01996365T AT E425745 T1 ATE425745 T1 AT E425745T1
Authority
AT
Austria
Prior art keywords
hyperglycaemic
medicine
microcapsules
antihyperglycamic
metformin
Prior art date
Application number
AT01996365T
Other languages
English (en)
Inventor
Catherine Castan
Remi Meyrueix
Gerard Soula
Original Assignee
Flamel Tech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flamel Tech Sa filed Critical Flamel Tech Sa
Application granted granted Critical
Publication of ATE425745T1 publication Critical patent/ATE425745T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01996365T 2000-11-17 2001-11-19 Medikament auf der basis von ein antihyperglykamikum enthaltenden mikrokapseln mit gesteuerter freisetzung ATE425745T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0014876A FR2816840B1 (fr) 2000-11-17 2000-11-17 Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation

Publications (1)

Publication Number Publication Date
ATE425745T1 true ATE425745T1 (de) 2009-04-15

Family

ID=8856604

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01996365T ATE425745T1 (de) 2000-11-17 2001-11-19 Medikament auf der basis von ein antihyperglykamikum enthaltenden mikrokapseln mit gesteuerter freisetzung

Country Status (13)

Country Link
US (1) US8197850B2 (de)
EP (1) EP1333816B1 (de)
JP (1) JP2004513913A (de)
CN (2) CN1853617A (de)
AT (1) ATE425745T1 (de)
AU (1) AU2002220796A1 (de)
BR (1) BR0115958A (de)
CA (1) CA2428782C (de)
DE (1) DE60138033D1 (de)
ES (1) ES2324205T3 (de)
FR (1) FR2816840B1 (de)
PT (1) PT1333816E (de)
WO (1) WO2002039984A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2822834B1 (fr) * 2001-04-02 2005-02-25 Flamel Tech Sa Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2837100B1 (fr) * 2002-03-18 2004-07-23 Flamel Tech Sa Comprimes a bases de microcapsules a liberation modifiee
EP1492511B3 (de) 2002-04-09 2012-05-02 Flamel Technologies Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
CN100577164C (zh) 2002-04-09 2010-01-06 弗拉梅技术公司 可改进释放阿莫西林的微囊含水混悬液形式的口服药物制剂
FR2843881B1 (fr) * 2002-09-02 2006-06-02 Flamel Tech Sa Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
FR2842736B1 (fr) 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
FR2842735B1 (fr) * 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
FR2843117B1 (fr) * 2002-07-30 2004-10-15 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques
ES2355233T3 (es) * 2002-09-28 2011-03-24 Mcneil-Ppc, Inc. Formas de dosificación de liberación modificada con dos núcleos y una abertura.
EP1510208A1 (de) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Metformin-Statin-Kombination enthaltende pharmazeutische Zusammensetzungen
FR2860516B1 (fr) * 2003-10-03 2006-01-13 Flamel Tech Sa Homopolyaminoacides telecheliques fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
FR2862536B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
NZ550171A (en) 2004-03-02 2009-05-31 Poly Coat Pty Ltd A multi-component paintable primer system incorporating a thermoplastic cellulose polymer
EP1591114A1 (de) * 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Verwendung von Metformin und Orlistat zur Behandlung oder Vorbeugung von Obesität
CN101602865B (zh) * 2009-03-13 2011-08-31 王懋 一种乙基纤维素混悬液及其制备方法与应用
AU2011224350B2 (en) * 2010-03-09 2015-07-02 Alkermes Pharma Ireland Limited Alcohol resistant enteric pharmaceutical compositions
US8581001B2 (en) 2010-04-16 2013-11-12 Codman & Shurtleff Metformin-cysteine prodrug
WO2013077821A1 (en) * 2011-11-23 2013-05-30 Mahmut Bilgic Homogeneous biguanide composition
CN103637999B (zh) * 2013-12-12 2014-12-03 南通联亚药业有限公司 一种多层固体药物剂型
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US20180104197A9 (en) 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
WO2016016845A1 (en) 2014-07-30 2016-02-04 Sun Pharmaceutical Industries Limited Dual-chamber pack
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
WO2015166473A1 (en) 2014-05-01 2015-11-05 Sun Pharmaceutical Industries Limited Extended release suspension compositions
EP3288539A4 (de) * 2015-05-01 2019-07-10 Sun Pharmaceutical Industries Ltd Flüssige retard-zusammensetzungen von metformin
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
FR3055800B1 (fr) * 2016-09-15 2020-06-26 Unither Pharmaceuticals Composition solide a ingestion rapide et deglutition facilitee, sous forme de particules solides non agglomerees, comprenant deux differents types de particules
AU2019232145A1 (en) * 2018-03-07 2020-10-01 Teagasc - The Agriculture And Food Development Authority A composition for type II diabetics and for use in providing sustained energy release over time

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
DE3543999A1 (de) 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
GB9104854D0 (en) * 1991-03-07 1991-04-17 Reckitt & Colmann Prod Ltd Sustained release compositions
ATE154241T1 (de) * 1991-10-01 1997-06-15 Takeda Chemical Industries Ltd Mikropartikeln-zusammenfassung zur verlängerten freigabe und herstellung derselbe
JP3277342B2 (ja) * 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
US5594016A (en) 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
JPH08151322A (ja) * 1994-09-30 1996-06-11 Takeda Chem Ind Ltd 経口徐放剤
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
IT1276130B1 (it) 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US20030064108A1 (en) 1996-04-23 2003-04-03 Stefan Lukas Taste masked pharmaceutical compositions
AU729529B2 (en) 1997-06-06 2001-02-01 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
EA003101B1 (ru) * 1998-03-19 2002-12-26 Бристол-Майерз Сквибб Компани Двухфазная система доставки с регулируемым высвобождением для фармацевтических средств с высокой растворимостью и способ лечения диабета с помощью этой системы
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
ATE250418T1 (de) 1998-07-15 2003-10-15 Merck Sante Sas Tabletten enthaltend eine kombination von glibenclamid und metformin
US6099862A (en) 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
JP2000085159A (ja) 1998-09-14 2000-03-28 Ricoh Co Ltd 画像処理方法
BR9915285A (pt) * 1998-11-12 2001-08-07 Smithkline Beecham Plc Composição farmacêutica para liberação modificada de um sensitivador de insulina e um outro agente antidiabético
DE19860698A1 (de) 1998-12-30 2000-07-06 Hexal Ag Neue pharmazeutische Zusammensetzung
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6428809B1 (en) 1999-08-18 2002-08-06 Microdose Technologies, Inc. Metering and packaging of controlled release medication
CO5200844A1 (es) 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
HU229352B1 (en) 1999-11-03 2013-11-28 Bristol Myers Squibb Co Medicament comprising the combination of metformin and glyburide
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
KR20020063282A (ko) * 1999-12-28 2002-08-01 아지노모토 가부시키가이샤 경구 투여용 당뇨병 치료제
FR2811571B1 (fr) * 2000-07-11 2002-10-11 Flamel Tech Sa Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
FR2825023B1 (fr) 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif

Also Published As

Publication number Publication date
AU2002220796A1 (en) 2002-05-27
DE60138033D1 (de) 2009-04-30
PT1333816E (pt) 2009-06-23
BR0115958A (pt) 2004-01-06
JP2004513913A (ja) 2004-05-13
EP1333816A2 (de) 2003-08-13
ES2324205T3 (es) 2009-08-03
CN1853617A (zh) 2006-11-01
WO2002039984A3 (fr) 2002-07-11
CN1474687A (zh) 2004-02-11
US20040175424A1 (en) 2004-09-09
FR2816840A1 (fr) 2002-05-24
CA2428782A1 (fr) 2002-05-23
CA2428782C (fr) 2013-01-08
EP1333816B1 (de) 2009-03-18
WO2002039984A2 (fr) 2002-05-23
FR2816840B1 (fr) 2004-04-09
US8197850B2 (en) 2012-06-12

Similar Documents

Publication Publication Date Title
ATE425745T1 (de) Medikament auf der basis von ein antihyperglykamikum enthaltenden mikrokapseln mit gesteuerter freisetzung
CA2130464C (en) Topical aromatic releasing compositions
Sajan et al. Chronotherapeutics and chronotherapeutic drug delivery systems
Ahad et al. Transdermal delivery of antidiabetic drugs: formulation and delivery strategies
Tripathi Essentials of pharmacology for dentistry
ATE48598T1 (de) Gewisse 3-(5-aminopentyl)-amino-1-benzazepin-2-on-1-alk nsaeuren, verfahren zu ihrer herstellung, pharmazeutische praeparate enthaltend diese verbindungen, sowie ihre therapeutische verwendung.
CN102143687A (zh) 4-氨基吡啶在改善具有脱髓鞘和其它神经***状况的患者的神经-认知和/或神经-精神病学损伤中的用途
DE3814532A1 (de) Dhp-retard-zubereitung
Tönder et al. Sulfonamide-induced chronic liver disease
Shukla et al. Transdermal delivery via medical device technologies
DE69530673T2 (de) Verhütung oder Verminderung von Photosensitivität oder phototoxischen Reaktionen auf antiinfektiöse Medikamente
Jackson et al. Another abusable amphetamine
Hitselberger et al. Photosensitivity due to chlorpropamide
DE69008107D1 (de) Zubereitung mit verzögerter Freigabe eines Hydrochlorids eines basischen Arzneistoffs.
De Haen The drug lag—Does it exist in Europe?
DE69516706D1 (de) Bis-2-aminopyridine, verfahren zu ihrer herstelung und ihre verwendung zur bekämpfung von parasitosen
JPH0327313A (ja) 生理的用量のビタミンａと治療活性のある各種有効成分とを有する組成物
Heilmann Innovations in drug delivery systems
Mir et al. Epilepsy and Neuroinflammation: Unraveling the Complex Connection
Townsend et al. Continuing rise in emergency admissions. Visiting elderly patients at home immediately after discharge reduces emergency readmissions.
Torrens et al. Parotid swelling and terbinafine.
Alván et al. The validity of the sigmoid Emax model and efficiency concept in diuretic studies.
Suresh et al. Oral film technology: a perspective on translational research and clinical studies
SU980720A1 (ru) Способ лечени больных лепрой
DE60013638T2 (de) Oral verabreichbares pharmazeutisches Produkt und Verfahren zu seiner Herstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1333816

Country of ref document: EP